Literature DB >> 1382345

HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions.

S J Ghim1, A B Jenson, R Schlegel.   

Abstract

Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or nonconformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57 kDa), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382345     DOI: 10.1016/0042-6822(92)91251-o

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

Review 1.  Human papillomavirus vaccination: a case study in translational science.

Authors:  Allyson K Palmer; Antoneicka L Harris; Robert M Jacobson
Journal:  Clin Transl Sci       Date:  2014-05-19       Impact factor: 4.689

2.  Human papillomavirus infection.

Authors:  J F Hines; S J Ghim; A B Jenson
Journal:  BMJ       Date:  1996-03-02

Review 3.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

4.  Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.

Authors:  Michael Berg; Julie Difatta; Egbert Hoiczyk; Richard Schlegel; Gary Ketner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

Review 5.  The history of tumor virology.

Authors:  Ronald T Javier; Janet S Butel
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

6.  Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts.

Authors:  C E Greer; C M Wheeler; M B Ladner; K Beutner; M Y Coyne; H Liang; A Langenberg; T S Yen; R Ralston
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

7.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Factors influencing the willingness of US women to vaccinate their daughters against the human papillomavirus to prevent cervical cancer.

Authors:  Jennifer Y Lai; Anna V Tinker; Winson Y Cheung
Journal:  Med Oncol       Date:  2013-04-23       Impact factor: 3.064

9.  Development of a 2-plex luminex-based competitive immunoassay to quantify neutralizing antibodies induced by virus-like particles for human papillomavirus 16 and 18.

Authors:  Pin Lv; Hongmei Zhu; Hongfang Wang; George Wang
Journal:  J Biomed Biotechnol       Date:  2011-07-25

10.  Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.

Authors:  Archana Monie; Chien-Fu Hung; Richard Roden; T-C Wu
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.